VEGFA and hemorrhage: However, following intravitreal bevacizumab (anti-vascular endothelial growth factor treatment), there was observed regression of radiation retinopathy manifestations, including hemorrhage, exudates, intraretinal microangiopathy, and macular edema, without apparent impact on capillary nonperfusion.